Impact of molecular imaging on the diagnostic process in a memory clinic
| Autor: | Marcel M. Verbeek, Albert D. Windhorst, Niels D. Prins, Philip Scheltens, Otto S. Hoekstra, Adriaan A. Lammertsma, Frans R.J. Verhey, Claire A. G. Wolfs, Afina W. Lemstra, Bart N.M. van Berckel, Sofie F. Adriaanse, Mark A. van Buchem, Ron Handels, Wiesje M. van der Flier, Rik Ossenkoppele, Yolande A.L. Pijnenburg, Pauline Aalten |
|---|---|
| Přispěvatelé: | Psychiatrie & Neuropsychologie, Promovendi MHN, MUMC+: MA Med Staf Spec Psychiatrie (9), RS: MHeNs School for Mental Health and Neuroscience, Neurology, Radiology and nuclear medicine, NCA - Brain imaging technology, NCA - neurodegeneration |
| Jazyk: | angličtina |
| Rok vydání: | 2013 |
| Předmět: |
Male
Fluorine Radioisotopes Epidemiology chemistry.chemical_compound Outpatient clinic Carbon Radioisotopes Prospective Studies education.field_of_study Aniline Compounds medicine.diagnostic_test SMC Health Policy Memory clinic Brain FTD Middle Aged Alzheimer's disease Molecular Imaging Psychiatry and Mental health Treatment Outcome Positron emission tomography Frontotemporal Dementia Disease Progression Female France Lewy body dementia Psychology Frontotemporal dementia Lewy Body Disease Outpatient Clinics Hospital DCN MP - Plasticity and memory Population Sensitivity and Specificity Diagnosis Differential Cellular and Molecular Neuroscience Developmental Neuroscience Alzheimer Disease Fluorodeoxyglucose F18 medicine Dementia Humans education DCN NN - Brain networks and neuronal communication Aged Memory Disorders [C-11]PIB Lewy body [F-18]FDG business.industry medicine.disease MCI Thiazoles Early Diagnosis PET chemistry Positron-Emission Tomography Neurology (clinical) Geriatrics and Gerontology Radiopharmaceuticals Nuclear medicine business Pittsburgh compound B Follow-Up Studies |
| Zdroj: | Alzheimer's and Dementia, 9(4), 414-421 Alzheimer's & Dementia, 9, 414-21 Alzheimer's & Dementia, 9(4), 414-421. Elsevier Science Ossenkoppele, R, Prins, N D, Pijnenburg, Y A L, Lemstra, A W, van der Flier, W M, Adriaanse, S F, Windhorst, A D, Handels, R L H, Wolfs, C A G, Aalten, P, Verhey, F R J, Verbeek, M M, van Buchem, M A, Hoekstra, O S, Lammertsma, A A, Scheltens, P & van Berckel, B N M 2013, ' Impact of molecular imaging on the diagnostic process in a memory clinic ', Alzheimers & Dementia, vol. 9, no. 4, pp. 414-421 . https://doi.org/10.1016/j.jalz.2012.07.003 Alzheimers & Dementia, 9(4), 414-421. Elsevier Alzheimer's & Dementia, 9, 4, pp. 414-21 |
| ISSN: | 1552-5260 |
| DOI: | 10.1016/j.jalz.2012.07.003 |
| Popis: | Contains fulltext : 116532.pdf (Publisher’s version ) (Open Access) BACKGROUND: [(11)C]Pittsburgh compound B ([(11)C]PIB) and [(18)F]-2-fluoro-2-deoxy-D-glucose ([(18)F]FDG) PET measure fibrillar amyloid-beta load and glucose metabolism, respectively. We evaluated the impact of these tracers on the diagnostic process in a memory clinic population. METHODS: One hundred fifty-four patients underwent paired dynamic [(11)C]PIB and static [(18)F]FDG PET scans shortly after completing a standard dementia screening. Two-year clinical follow-up data were available for 39 patients. Parametric PET images were assessed visually and results were reported to the neurologists responsible for the initial diagnosis. Outcome measures were (change in) clinical diagnosis and confidence in that diagnosis before and after disclosing PET results. RESULTS: [(11)C]PIB scans were positive in 40 of 66 (61%) patients with a clinical diagnosis of Alzheimer's disease (AD), 5 of 18 (28%) patients with frontotemporal dementia (FTD), 4 of 5 (80%) patients with Lewy body dementia, and 3 of 10 (30%) patients with other dementias. [(18)F]FDG uptake patterns matched the clinical diagnosis in 38 of 66 (58%) of AD patients, and in 6 of 18 (33%) FTD patients. PET results led to a change in diagnosis in 35 (23%) patients. This only occurred when prior diagnostic certainty was |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|